Actelion Pharmaceuticals Ltd. is a Swiss biopharmaceutical company specializing in treatments for rare diseases. Based in Allschwil, Switzerland, Actelion is a global leader in cardiovascular and respiratory diseases. Available in over 50 countries, including Pakistan, Actelion's innovative therapies improve patients' lives. Read More
Actelion is a Swiss biopharmaceutical company focusing on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs.
Founded in 1997 in Allschwil, Switzerland
Pioneered groundbreaking therapies for pulmonary arterial hypertension (PAH)
In 2017, Actelion was acquired by Johnson & Johnson for $30 billion
Gilead Sciences is an American biopharmaceutical company that researches, develops and commercializes drugs for HIV/AIDS, liver diseases, hematology and oncology, inflammatory, and respiratory diseases.
Novartis is a Swiss multinational pharmaceutical company that develops and manufactures drugs for various therapeutic areas including oncology, immunology, neuroscience, and cardiovascular.
Bayer is a German multinational pharmaceutical and life sciences company that develops and produces medications, crop protection chemicals, and seeds.
Tracleer is a prescription medication used to treat pulmonary arterial hypertension by reducing blood pressure in the lungs and increasing exercise capacity.
Opsumit is a prescription medication used to treat pulmonary arterial hypertension by reducing blood pressure in the lungs and improving exercise capacity.
Uptravi is a prescription medication used to treat pulmonary arterial hypertension by reducing blood pressure in the lungs.
Actelion is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion's main products include Tracleer, Opsumit, and Uptravi, which are all medications used to treat pulmonary arterial hypertension.
Actelion's competitors include Gilead Sciences, Novartis, Bayer, and other pharmaceutical companies developing drugs for similar therapeutic areas.
Pulmonary arterial hypertension (PAH) is a rare, progressive lung disease characterized by high blood pressure in the lungs, leading to shortness of breath, fatigue, and other symptoms.
Actelion was acquired by Johnson & Johnson in 2017 for $30 billion.
Express ShippingFast Delivery
Standard Shipping10+ Business Days